AUG 31, 2017 7:00 AM PDT

Characterization of H4-IC31 candidate: particles and composition

Speakers
  • Associate Scientist at SGS Canada and Sanofi Pasteur Ltd., Toronto, ON
    Biography
      Sasmit Deshmukh is an Associate Scientist at SGS Canada and Sanofi Pasteur Ltd., Toronto, ON. He received his PhD in Chemistry at Concordia University, Montreal, QC. He has over 10 years of extensive multidisciplinary research experience in chemistry, biochemistry and biophysics.
    • Head of Biophysics and Conformation Unit, Biochemistry Platform, Analytical R&D North America, Sanofi Pasteur Ltd
      Biography
        Marina Kirkitadze is Head of Biophysics and Conformation Unit, Biochemistry Platform, Analytical R&D North America, Sanofi Pasteur Ltd. She has 15 years' experience in the vaccine industry. Marina received her PhD in Biological Sciences at the Institute of Protein Research, Russian Academy of Sciences, Pushchino, Russia, and her MBA from the University of Phoenix, AZ, USA.

      Abstract:

      DATE: August 31, 2017
      TIME: 7:00am PT, 10:00am ET, 4:00pm CET

      A tuberculosis (TB) vaccine consisting of a recombinant fusion protein (referred to as H4) combined with a novel synthetic cationic adjuvant, IC31®, is in development. The H4 fusion protein consists of two immunogenic mycobacterial antigens, Ag85B and TB10.4. The IC31® adjuvant is a mixture of KLK, a leucine-rich peptide (KLKL5KLK), and the oligodeoxynucleotide ODN1a, a TLR9 ligand.  This webinar will discuss Phase Analysis Light Scattering (PALS) and Raman spectroscopy methods to characterize the H4-IC31 vaccine formulation. The PALS method can be used to assess vaccine product quality and consistency in terms of particle size, zeta potential and conductivity. These parameters can differentiate between the IC31® adjuvant and the H4-IC31 vaccine candidate; hence, the method can serve as a control during vaccine formulation. Additionally, Electrical Sensing Zone (ESZ) was used as an orthogonal method to measure size of IC31 and H4-IC31 particles. Furthermore structural changes of H4 protein upon adjuvantation were characterized by Raman, FTIR and CD spectroscopy. The applicability of these biophysical methods to characterize vaccine components in the final H4-IC31 drug product without desorption will be discussed. 


      Show Resources
      You May Also Like
      OCT 02, 2019 11:00 AM PDT
      OCT 02, 2019 11:00 AM PDT
      DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
      OCT 01, 2019 8:00 AM PDT
      C.E. CREDITS
      OCT 01, 2019 8:00 AM PDT
      DATE: October 1, 2019TIME: 8:00am PTIn the webinar, Introduction to Characterization of Biomolecules Using Analytical Ultracentrifugation, we discussed the fundamentals of analytical...
      SEP 05, 2019 4:00 PM CEST
      C.E. CREDITS
      SEP 05, 2019 4:00 PM CEST
      DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
      FEB 26, 2020 9:00 AM PST
      C.E. CREDITS
      FEB 26, 2020 9:00 AM PST
      DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
      NOV 18, 2019 7:00 AM PST
      C.E. CREDITS
      NOV 18, 2019 7:00 AM PST
      DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
      AUG 27, 2019 9:00 AM PDT
      C.E. CREDITS
      AUG 27, 2019 9:00 AM PDT
      DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
      Loading Comments...
      Show Resources